A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
Phase 3
Not yet recruiting
- Conditions
- Primary Hypercholesterolemia
- Interventions
- Drug: AD-2281Drug: AD-2282Drug: Placebo of AD-2282
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06747936
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
Phase 3
Completed
- Conditions
- Hypertension, EssentialPrimary Hypercholesterolemia
- Interventions
- Drug: AD-2021Drug: AD-2022Drug: AD-2022 PlaceboDrug: AD-2021 Placebo
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT06448962
- Locations
- 🇰🇷
Yonsei Cardiovascular Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
Phase 3
Not yet recruiting
- Conditions
- Essential Hypertension
- Interventions
- Drug: AD-227ADrug: AD-227BDrug: AD-227CDrug: Placebo of AD-227BDrug: Placebo of AD-227C
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT06441630
Phase III Study to Evaluate the Efficacy and Safety of AD-209
Phase 3
Recruiting
- Conditions
- Hypertension,Essential
- Interventions
- Drug: AD-209Drug: AD-2091Drug: AD-209 PlaceboDrug: AD-2091 Placebo
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06348576
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-224
Phase 3
Recruiting
- Conditions
- Hypertension,Essential
- Interventions
- Drug: AD-224ADrug: AD-224BDrug: AD-224CDrug: Placebo of AD-224BDrug: Placebo of AD-224ADrug: Placebo of AD-224C
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT06291207
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-223
Phase 3
Recruiting
- Conditions
- Hypertension,Essential
- Interventions
- Drug: AD-223ADrug: AD-223CDrug: AD-223BDrug: AD-223B PlaceboDrug: AD-223A PlaceboDrug: AD-223C Placebo
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 486
- Registration Number
- NCT06052748
- Locations
- 🇰🇷
Hanyang University Hospital, Seoul, Korea, Republic of
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Phase 1
Completed
- Conditions
- Gastro Esophageal Reflux
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06025773
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Assess the Safety and Pharmacokinetics of AD-104-A
Phase 1
Completed
- Conditions
- Hyperlipidemias
- Interventions
- Drug: AD-104-A
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05703282
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-209
Phase 2
Completed
- Conditions
- Hypertension, Essential
- Interventions
- Drug: AD-209-1CDrug: AD-209-1BDrug: AD-209Drug: AD-209-1ADrug: AD-209-1 placeboDrug: AD-209 placebo
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT05631990
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-218
Phase 3
Recruiting
- Conditions
- Mixed Dyslipidemia
- Interventions
- Drug: AD-218Drug: AD-218A
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT05400317
- Locations
- 🇰🇷
Yeongnam University Hospital, Daegu, Nam-gu, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath